Maratha Headlines

Cirrhosis Pipeline| 50+ Key Players & 50+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

 Breaking News
  • No posts were found

Cirrhosis Pipeline| 50+ Key Players & 50+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

November 22
18:43 2022
Cirrhosis Pipeline| 50+ Key Players & 50+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

DelveInsight’s, “Cirrhosis Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Cirrhosis Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Cirrhosis Pipeline clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Cirrhosis Pipeline Report

  • DelveInsight’s Cirrhosis Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Cirrhosis Companies are working such as GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co, Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
  • Promising Cirrhosis Pipeline therapies such as NGM282, IDN-6556, KB174, Maltodextrin, INT-747, ADSCs, Obeticholic Acid, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Allogeneic Mesenchymal Stem Cells, and others.
  • The Cirrhosis Companies and academics are working to assess challenges and seek opportunities that could influence Cirrhosis R&D. The Cirrhosis pipeline therapies under development are focused on novel approaches to treat/improve Cirrhosis.

 

Recent Developmental Activities on the Cirrhosis Pipeline

  • GXHPC1 therapy preparation contains adipose-derived mesenchymal stem cells (AD-MSCs) and was developed for the treatment of liver cirrhosis. The animal studies suggested that treatment of a diseased liver via GXHPC1 transplantation can abrogate liver fibrosis and facilitate recovery of liver function. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Liver Cirrhosis.
  • LPCS 1148 is an oral prodrug of bioidentical testosterone being developed for the management of symptoms associated with cirrhosis. Currently, the drug is in Phase II of clinical trial evaluation for the treatment of cirrhosis.
  • Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Currently, the drug is in Phase II/III stage of clinical trial evaluation for the treatment of Cirrhosis.

 

Request a sample and discover the recent breakthroughs happening Cirrhosis pipeline landscape @ Cirrhosis Pipeline Report

 

Cirrhosis Overview

Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis. There are, however, ways to prevent cirrhosis, because the diseases that most commonly lead to it progress slowly, and measures are available to prevent and treat them. Moreover, most cases of hepatocellular carcinoma (HCC) arise in a cirrhotic liver, so cirrhosis prevention is, in fact, also HCC prevention. Cirrhosis can arise in consequence of an exogenous/toxic, infectious, toxic/allergic, immunopathological/autoimmune, or vascular process or an inborn error of metabolism.

The typical findings in cirrhosis include: cutaneous signs of liver disease, a firm liver on palpation, and certain risk constellations such as: metabolic syndrome, heavy alcohol consumption and exposure to hepatotoxic substances. Early symptoms of cirrhosis may include: feeling tired or weak, poor appetite, losing weight without trying, nausea and vomiting and mild pain or discomfort in the upper right side of your abdomen. There’s no cure for cirrhosis at the moment. However, there are ways to manage the symptoms and any complications and slow its progression. Treating the problem that led to cirrhosis (for example, using anti-viral medicines to treat hepatitis C) can stop cirrhosis getting worse.

 

Cirrhosis Emerging Drugs

  • GXHPC 1: GWOXI Stem Cell Applied Technology
  • LPCN 1148: Lipocine
  • Belapectin: Galectin Therapeutics

 

Cirrhosis Pipeline Therapeutics Analysis

There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.

 

Learn more about the Cirrhosis emerging pipeline therapies @ Cirrhosis Clinical Trials

 

Cirrhosis Pipeline Therapeutic Assessment

  • CirrhosisPipeline Product Profiles
  • Cirrhosis PipelineTherapeutic Assessment
  • Cirrhosis Pipeline Assessment
  • Cirrhosis Inactive drugs assessment
  • Cirrhosis Unmet Needs

 

Scope of the Cirrhosis Pipeline Report

  • Coverage- Global
  • CirrhosisCompanies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co, Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
  • Cirrhosis Pipeline therapies- NGM282, IDN-6556, KB174, Maltodextrin, INT-747, ADSCs, Obeticholic Acid, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Allogeneic Mesenchymal Stem Cells, and others
  • Cirrhosis Key Companies
  • Cirrhosis Key Products
  • Cirrhosis- Unmet Needs
  • Cirrhosis- Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cirrhosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cirrhosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase II/III)
  8. Belapectin: Galectin Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GXHPC 1: GWOXI Stem Cell Applied Technology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cirrhosis Key Companies
  21. Cirrhosis Key Products
  22. Cirrhosis- Unmet Needs
  23. Cirrhosis- Market Drivers and Barriers
  24. Cirrhosis- Future Perspectives and Conclusion
  25. Cirrhosis Analyst Views
  26. Cirrhosis Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cirrhosis drugs?
  • How many Cirrhosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cirrhosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cirrhosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cirrhosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Cirrhosis pipeline therapeutics, reach out to @ Cirrhosis Treatment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/